Abstract:SHP2 (Src homology-2-containing protein tyrosine phosphatase 2) plays an important role in cell proliferation, survival, migration by affecting RAS-ERK, PI3K-AKT, JAK-STAT signaling pathways and so on. Overexpression or gene mutation of SHP2 is closely linked with a variety of cancers, making it a potential therapeutic target for cancer disease. In this paper, 30 target compounds bearing pyrido[1,2-a]pyrimidin-4-one core were synthesized via two-round design strategy by means of scaffold hopping protocol. It was evaluated the in vitro enzymatic inhibition and cell antiproliferation assay of these targets. 13a, designed in the first round, presented relatively good inhibitory activity, but its molecular rigidity might limit further improvement by hindering the formation of the desired "bidentate ligand", as revealed by molecular docking studies. In our second-round design, S atom as a linker was inserted into the core and the 7-aryl group to enhance the flexibility of the structure. The screening result revealed that 14i could exhibit high enzymatic activity against full-length SHP2 (IC50 = 0.104 μM), while showing low inhibitory effect on SHP2-PTP (IC50 > 50 μM). 14i also demonstrated high antiproliferative activity against the Kyse-520 cells (IC50 = 1.06 μM) with low toxicity against the human brain microvascular endothelial cells HBMEC (IC50 = 30.75 μM). 14i also displayed stronger inhibitory activities on NCI-H358 and MIA-PaCa2 cells compared to that of SHP099. Mechanistic studies revealed that 14i could induce cell apoptosis, arrest the cell cycle at the G0/G1 phase and downregulate the phosphorylation levels of Akt and Erk1/2 in Kyse-520 cells. Molecular docking and molecular dynamics studies displayed more detailed information on the binding mode and binding mechanism of 14i and SHP2. These data suggest that 14i has the potential to be a promising lead compound for our further investigation of SHP2 inhibitors.

Design, Synthesis and Biological Activity Testing of Library of Sphk1 Inhibitors

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

Design, Synthesis and Biological Evaluation of Thienopyridinones As Chk1 Inhibitors

Discovery of Potent, Orally Active Compounds of Tyrosine Kinase and Serine/Threonine-Protein Kinase Inhibitor with Anti-Tumor Activity in Preclinical Assays

Design, Syntheses and Biological Evaluation of Natural Product Aiphanol Derivatives and Analogues: Discovery of Potent Anticancer Agents

Design, Synthesis, Antitumor Activity Evaluation, and Molecular Dynamics Simulation of Some 2-Aminopyrazine Derivatives

Design, Synthesis, and Biological Evaluation of Orally Bioavailable CHK1 Inhibitors Active against Acute Myeloid Leukemia

Design, Synthesis and Biological Evaluation of Benzyloxyphenyl-Methylaminophenol Derivatives As STAT3 Signaling Pathway Inhibitors.

Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer

Design, Synthesis, and Biological Evaluation of 2‐Aminothiazole Derivatives as Novel Checkpoint Kinase 1 (CHK1) Inhibitors

Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2- d ]pyrimidine derivatives as Mnk1/2 inhibitors

Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors.

Design, Synthesis, and Biological Evaluation of Pyrido[2,3- d ]pyrimidin-7(8 H )-one Derivatives As Potent USP1 Inhibitors

Novel Sphingosine Kinase 1 Inhibitor Suppresses Growth of Solid Tumor and Inhibits the Lung Metastasis of Triple-Negative Breast Cancer

Design, synthesis and biological evaluation of novel benzimidazole-derived p21-activited kinase 4 (PAK4) inhibitors bearing a 4-(4-methylpiperazin-1-yl)phenyl scaffold as potential antitumor agents

Structure-based Design, Synthesis and Biological Evaluation of Diphenylmethylamine Derivatives As Novel Akt1 Inhibitors

Design, synthesis, and biological evaluation of Pyrido[1,2-a]pyrimidin-4-one derivatives as novel allosteric SHP2 inhibitors

Design, Synthesis and Biological Evaluation of (R)-5-methylpyrrolidin-2-ones As P300 Bromodomain Inhibitors with Anti-Tumor Activities in Multiple Tumor Lines.

Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FAK inhibitors for the potential treatment of pancreatic cancer